Objective: Rare cases of Hodgkin`s lymphoma have been reported in the setting of inflammatory bowel disease. Method: We report a case of Hodgkin`s lymphoma in a 37 years old male patient with corticosteroid-dependent Crohn´Disease (CD) who had been medicated with azathioprine for many years. In the last 4 years he began periodical therapy with infliximab, till the time when he complained of worsening of symptoms and the appearance of asthenia, tenesmus and weight loss. Infliximab was withdrawn and replaced by adalimumab. A colonoscopy with several biopsies revealed the presence of a Hodgkin Lymphoma. Results: The histological examination revealed granulation tissues where we identified atypical cells (Reed-Sternberg cells) with the following immunohistological staining: CD30+, CD15+, LMP1 + LCA-, CD20-, CD3-, ALK-. These results in conjunction with the morphological aspects and the clinical history of CD favored the diagnosis of Hodgkin Lymphoma in a patient with preceding CD. The patient was subjected to radical colectomy. Postoperative pathological examination showed CD with involvement of the distal rectum by Hodgkin's lymphoma. Conclusion: The present report may serve as a reminder to clinicians of the possibility of occult lymphoma in patients with colonic CD treated with biological therapy. Objective: DNA mismatch repair (MMR) status in sporadic colonic cancers (CCs) had provided valuable prognostic and predictive information in the appropriate clinical setting; however there are no definitive guidelines for microsatellite instability (MSI) testing. We evaluated the expression of MMR proteins and correlated them with outcome in a cohort of patients with sporadic colon cancer. Method: We reviewed 352 cases of sporadic stage II colonic cancer from Abril 27th 1995 to December 12th 2009. Clinical data including tumor grade, prognostic factors, therapy and outcome were searched for. Tissue microarrays using a manual Beecher system were constructed and stained with antibodies for MLH1, MSH2, PMS2 and MSH6. Results: 8 % (28) of 352 CCs had loss of expression of one or more MMR proteins, including defect in 1 protein 3.7 % (13), 2 proteins 3,7 % (13) and tree proteins 0,6 %(2). The mean overall survival was 144 months with no significant differences in patients between microsatellite stable and unstable tumors. Conclusion: We detected a fairly low prevalence of the loss of immunohistochemical expression of MMR proteins. This result might have influence our mean overall survival between microsatellite stable and unstable tumors.